Simply Wall St.
Assessing Amicus Therapeutics (FOLD) Valuation as Shares Gain 11% Over Past Month
📊
AI Sentiment
Positive
7/10
- Home
- FOLD
as of 12-04-2025 3:45pm EST
$9.92
+$0.13
+1.38%
Amicus Therapeutics Inc is a patient-dedicated biotechnology company focused on discovering, developing and delivering novel high-quality medicines for people living with rare diseases. With extraordinary patient focus, the company is committed to advancing and expanding a pipeline of cutting-edge medicines for rare diseases. It has a portfolio of product opportunities, including oral precision medicine for people living with Fabry disease who have amenable genetic variants; a clinical-stage, treatment paradigm for Pompe disease, and a rare disease gene therapy portfolio. The company has one segment focused on the discovery, development, and commercialization of therapies to treat a range of devastating rare and orphan diseases.
Chart Type:
Time Range:
| Founded: | 2002 | Country: | United States |
| Employees: | N/A | City: | PRINCETON |
| Market Cap: | 2.5B | IPO Year: | 2007 |
| Target Price: | $30.29 | AVG Volume (30 days): | 4.6M |
| Analyst Decision: | Buy | Number of Analysts: | 7 |
| Dividend Yield: | N/A | Dividend Payout Frequency: | N/A |
| EPS: | -0.05 | EPS Growth: | N/A |
| 52 Week Low/High: | $5.51 - $10.57 | Next Earning Date: | 11-04-2025 |
| Revenue: | $598,704,000 | Revenue Growth: | 21.28% |
| Revenue Growth (this year): | 21.12% | Revenue Growth (next year): | 21.23% |
AI-Powered FOLD Daily Prediction
Machine learning model trained on 25+ technical indicators
Updated a day ago
AI Recommendation
hold
Model Accuracy: 70.75%
70.75%
Confidence
Disclaimer: This prediction is generated by an AI model and should not be considered as financial advice. Always conduct your own research and consult with financial professionals before making investment decisions.
Stock Insider Trading Activity of Amicus Therapeutics Inc. (FOLD)
Campbell Bradley L
Sell
President and CEO
FOLD Dec 1, 2025
Avg Cost/Share
$10.01
Shares
14,587
Total Value
$146,011.49
Owned After
1,137,282
SEC Form 4
Clark David Michael
Sell
Chief People Officer
FOLD Nov 4, 2025
Avg Cost/Share
$9.51
Shares
25,643
Total Value
$243,859.80
Owned After
322,618
SEC Form 4
| Insider | Ticker | Relationship | Date | Transaction | Avg Cost | Shares | Total Value | Owned After | SEC Forms |
|---|---|---|---|---|---|---|---|---|---|
| Campbell Bradley L | FOLD | President and CEO | Dec 1, 2025 | Sell | $10.01 | 14,587 | $146,011.49 | 1,137,282 | |
| Clark David Michael | FOLD | Chief People Officer | Nov 4, 2025 | Sell | $9.51 | 25,643 | $243,859.80 | 322,618 |
Latest Amicus Therapeutics Inc. News
FOLD Breaking Stock News: Dive into FOLD Ticker-Specific Updates for Smart Investing
Simply Wall St.
How Strong Galafold and Pombiliti Sales Helped Amicus Therapeutics (FOLD) Surpass Expectations and Shift Its Outlook
📊
AI Sentiment
Positive
7/10
Compare FOLD vs Leading Stocks
See how FOLD stacks up against similar companies in the market
Head-to-Head Comparisons
Share on Social Networks:
Tools & Resources
Enhance your trading experience with our free tools
Disclaimer
The information presented on this page, "FOLD Amicus Therapeutics Inc. - Stocks Price | History | Analysis", including historical data, forecasts, news, insider information, and predictions, is provided for educational purposes only. It should not be considered as financial advice or a recommendation to buy or sell any securities. Decisions regarding investments should be made only after careful consideration and consultation with a qualified financial advisor. We do not endorse or guarantee the accuracy or reliability of the information provided, and we disclaim any liability for financial losses incurred as a result of decisions made based on the information presented.